WSJ Tech News Briefing · Monday, July 27, 2026
AstraZeneca announced higher sales in the second quarter, primarily due to the performance of its cancer medications. The company is also preparing to provide updates on numerous high-profile studies that could enhance its future portfolio.
“The company also reported higher second quarter sales today, driven by its cancer medicines.”
“AstraZeneca is due to provide updates on 20 high-profile studies over the next year and a half, with potential to strengthen its portfolio beyond 2030.”